NEJM Studies Find New Carbamazepine Response Marker, Support Value of Genotyping in Han Chinese

The US Food and Drug Administration in 2007 updated the label for carbamazepine to recommend that patients of Asian ancestry taking the drug be tested for the HLA-B*1502 marker. While one NEJM study published this week supports this practice, a second study suggests that the boxed warning be expanded to include a new allele for the European population.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.